PT  - JOURNAL ARTICLE
AU  - Geiger, Sabine
AU  - Hirsch, Daniela
AU  - Hermann, Felix G.
TI  - Cell therapy for lung disease
AID  - 10.1183/16000617.0044-2017
DP  - 2017 Jun 30
TA  - European Respiratory Review
PG  - 170044
VI  - 26
IP  - 144
4099  - http://err.ersjournals.com/content/26/144/170044.short
4100  - http://err.ersjournals.com/content/26/144/170044.full
SO  - EUROPEAN RESPIRATORY REVIEW2017 Jun 30; 26
AB  - Besides cancer and cardiovascular diseases, lung disorders are a leading cause of morbidity and death worldwide. For many disease conditions no effective and curative treatment options are available. Cell therapies offer a novel therapeutic approach due to their inherent anti-inflammatory and anti-fibrotic properties. Mesenchymal stem/stromal cells (MSC) are the most studied cell product. Numerous preclinical studies demonstrate an improvement of disease-associated parameters after MSC administration in several lung disorders, including chronic obstructive pulmonary disease, acute respiratory distress syndrome and idiopathic pulmonary fibrosis. Furthermore, results from clinical studies using MSCs for the treatment of various lung diseases indicate that MSC treatment in these patients is safe. In this review we summarise the results of preclinical and clinical studies that indicate that MSCs are a promising therapeutic approach for the treatment of lung diseases. Nevertheless, further investigations are required.Cell-based therapies for lung diseases are evolving to become viable treatment options for clinical application http://ow.ly/oXe130crWmw